Fluent Bio
4 known investors
Fluent Bio develops software for analyzing single-cell RNA sequencing data, producing count matrices and diagnostic outputs for researchers using Illumina sequencing libraries. The software is designed for genomics and life science researchers working with single-cell gene expression data.
Investors · 4
Competitors · 3
by search overlap
IDbyDNA13 shared keywordsScalable, high throughput DNA sequencing platforms.
10x Genomics 1-color9 shared keywords10x Genomics offers single cell analysis technology, including its Flex assay and Flex Apex product, which use probe-based chemistry and plate-based multiplexing to profile fresh, frozen, and FFPE samples for researchers. The tools support applications in cancer, immunology, and neuroscience, enabling gene expression and multiomic profiling of cell surface protein, intracellular protein, and CRISPR guides.
Oup8 shared keywordsOxford University Press publishes research, educational, and reference materials, including reports on reading and children's learning, and reference resources such as its dictionary "Word of the Day." It serves readers, educators, and learners across a wide range of subjects worldwide.
Companies competing with Fluent Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 6 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $1.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $399.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $299.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $288.4K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Fluent Bio do?
- Fluent Bio develops software for analyzing single-cell RNA sequencing data, producing count matrices and diagnostic outputs for researchers using Illumina sequencing libraries. The software is designed for genomics and life science researchers working with single-cell gene expression data.
- Who are Fluent Bio's investors?
- Fluent Bio's investors include Civilization Ventures Management, Llc, Cota Capital, Illumina Ventures, Samsara BioCapital.